Bhowmick and Girotti [56] and Fahey and Girotti [57] recently demonstrated that two prostate carcinoma cell lines, PC3 and DU145, could also exploit iNOS-generated NO for resistance to PDT cytotoxicity. This evidence concerns the gene NOS2 and prostate carcinoma.